Andrew Schwab Sells 114,700 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Director Andrew Schwab sold 114,700 shares of the business’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $4.54, for a total transaction of $520,738.00. Following the completion of the transaction, the director owned 2,465,298 shares in the company, valued at approximately $11,192,452.92. This trade represents a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

CAMP4 Therapeutics Price Performance

NASDAQ CAMP opened at $4.48 on Friday. The stock’s 50 day simple moving average is $4.12 and its 200 day simple moving average is $4.34. The firm has a market cap of $281.12 million, a PE ratio of -1.93 and a beta of 0.22. CAMP4 Therapeutics Corporation has a one year low of $1.41 and a one year high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). The business had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. As a group, equities analysts expect that CAMP4 Therapeutics Corporation will post -0.57 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on CAMP shares. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and raised their price target for the company from $5.00 to $9.00 in a report on Tuesday, June 16th. Zacks Research raised CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 17th. Weiss Ratings upgraded shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. Piper Sandler reaffirmed an “overweight” rating and issued a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Finally, UBS Group set a $15.00 price target on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $9.56.

Institutional Investors Weigh In On CAMP4 Therapeutics

A number of hedge funds have recently modified their holdings of CAMP. Jupiter Topco LLC acquired a new position in shares of CAMP4 Therapeutics in the 2nd quarter valued at approximately $27,581,000. Janus Henderson Group PLC raised its holdings in CAMP4 Therapeutics by 35.9% during the 4th quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider’s stock worth $38,807,000 after buying an additional 1,666,666 shares during the period. 5AM Venture Management LLC acquired a new stake in CAMP4 Therapeutics during the 2nd quarter worth approximately $25,647,928,000. Vivo Capital LLC lifted its stake in CAMP4 Therapeutics by 8.3% in the fourth quarter. Vivo Capital LLC now owns 4,246,568 shares of the Wireless communications provider’s stock valued at $26,031,000 after buying an additional 325,000 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in CAMP4 Therapeutics in the fourth quarter valued at approximately $14,938,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.